Skip to main content
Premium Trial:

Request an Annual Quote

Abbott's MDx Sales Jump 19 Percent in Q2

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Abbott today reported that its second-quarter molecular diagnostics sales increased around 19 percent year over year.

The firm posted total molecular diagnostics sales of $105 million for the three-month period ended June 30, compared to $89 million for Q2 2010. Of the $105 million, $45 million of the sales came from the US with the remainder coming from international markets.

The firm reiterated its plans to launch more than 12 new molecular diagnostics products, including oncology and infectious disease assays, over the next few years. It noted that it has submitted for regulatory clearance an ALK gene rearrangement test for non-small cell lung cancer to be used in combination with Pfizer's crizotinib.

Overall, Abbott reported Q2 sales of $9.62 billion, up 9 percent from $8.83 billion for the prior-year second quarter. Its net earnings rose to $1.94 billion, or $1.23 per share, from $1.29 billion, or $.83 per share.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.